The latest articles, press releases and dossiers on diagnostics in Baden-Württemberg
Article - 24-Sep-2015
The number of people suffering from oral or oropharyngeal cancer is rising steadily. The major cause of these cancers is human papillomaviruses (HPV) that colonise the oral cavity, where they are difficult to detect. QIAGEN Lake Constance GmbH from Stockach, in cooperation with Abviris Deutschland GmbH, has developed a new test system to improve the detection of oral HPV. This new system enables rapid and reliable quantitative detection of HPV-specific antibodies outside of a central laboratory and is intended to make it possible in the future to initiate cancer treatment at an early stage.
Article - 21-Sep-2015
Nanoparticles are already used in many materials and areas, ranging from textiles to scientific and medical research. The global scientific community is keenly interested in nanoparticle research and Prof. Dr. Hans-Peter Deigner, professor in the Faculty of Medical and Life Sciences at Furtwangen University of Applied Sciences (HFU) is no exception. Deigner works on optimising nanoparticles for application in lateral flow assays. As well as carrying out intensive research into biomarkers, Deigner is also dean of the HFU’s Faculty of Medical and Life Sciences and president of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB).
Press release - 18-Sep-2015
Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the development of the operating production and sales activities as well as the further advancements of Biametrics’ label- free analytical devices for the life science market.
Article - 29-Jun-2015
Prof. Dr. Rohini Kuner and fellow scientists from Heidelberg have shown that a protein that inhibits an enzyme produced by immune cells protects nerve cells from chronic hypersensitivity to neuropathic pain. Kuner is also the spokesperson of a new collaborative research centre in Heidelberg that is receiving funding from the German Research Foundation totalling over 12 million euros. The centre is seeking to find the reasons why acute pain becomes chronic and how this transition can be reversed or prevented.
Article - 22-Jun-2015
Physicist Dr. Jan-Bernd Hövener makes magnetic resonance imaging devices smaller and their magnetic fields weaker in the hope that precisely these properties will help him detect abnormal metabolic processes and tumours. On 9th June 2015, the International Organisation for Medical Physics (IOMP) awarded Hövener the Young Scientist Award in Medical Physics, the organisation’s most important prize for up-and-coming scientists.
Article - 15-Jun-2015
Since January 2015, Tübingen has been home to a Centre for Personalised Medicine (ZPM). Twenty-three institutes and hospitals have joined forces to improve diagnosis of disease and develop individualised treatments for patients with a variety of diseases. In parallel, the centre also develops new diagnostic strategies. This means, for example, that data derived from the analysis of the entire genetic material of cells, proteins and metabolic processes are taken into account when stratifying patient therapy.
Article - 26-May-2015
Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease in men and women in Germany. A particularly aggressive form occurs when a mutation is present in the proto-oncogene BRAF. As part of the Collaborative Research Centre 850 at the Institute of Molecular Medicine and Cell Research at the University of Freiburg, Dr. Ricarda Herr and Dr. Tilman Brummer are trying to find out how a mutated BRAF gene contributes to the development and growth of colorectal cancer.
Article - 11-May-2015
Lung cancer is one of the most common malignant diseases and one of the leading causes of cancer-related deaths worldwide. 90% of all lung cancer cases in men and 80% in women are due to long-term exposure to tobacco smoke. In Germany, around 140 new cases are diagnosed every day, and 50,000 people die of lung cancer every year. PD Dr. Gian Kayser, senior consultant in the Department of Clinical Pathology at Freiburg University Medical Centre, studies the pathogenesis and biology of lung cancer. His aim is to develop new therapies. Kayser and his team have identified the protein MTSS1 as a prognostic factor that can be used to assess the aggressiveness of squamous cell carcinomas before they start to metastasise.
Article - 27-Apr-2015
Professor Martin Wabitsch from Ulm University Hospital has been studying the genetic causes of obesity for quite some time. The discovery of another cause of this complex condition that has key clinical consequences was recently published in the renowned New England Journal of Medicine. Despite the internationally acknowledged success of this research and in contrast to the view of the World Health Organisation and scientific organisations, the health ministry and health insurance companies in Germany still refuse to recognise the condition as a disease.
Article - 30-Mar-2015
Too much stress makes you sick – this is the widely held opinion. But exactly how chronic psychological stress affects our body is not yet fully understood. This is the question Dr. Annette Sommershof and her team from the University of Konstanz are trying to answer. The scientists are exploring stress-related changes in the immune system and have found evidence for the observation that long-term stress weakens the immune system, resulting in increased susceptibility to infections.
Article - 23-Mar-2015
cytena GmbH, a start-up company which was spun out from the Department of Microscystems Engineering (IMTEK) at the University of Freiburg in 2014, has developed a device that enables single cells to be deposited safely and gently using a single-cell printer called cy-Clone. Once processed, the cells can be used to study tumour heterogeneity and to create clonal cell lines for producing antibodies.
Press release - 07-Mar-2015
Thorough examination of the genome of cancer cells is essential for a better understanding of the disease and to improve treatment. Therefore, the German Cancer Research Center (DKFZ), with the support of the German Cancer Consortium (DKTK), will invest in the Illumina HiSeq X Ten Sequencing System, the world’s first and only platform to deliver full coverage human whole genome for less than 1000 Euros per genome with the power to sequence more than 18,000 genomes per year.